Stephen David Prior's most recent trade in AN2 Therapeutics Inc was a trade of 3,604 Common Stock done at an average price of $1.0 . Disclosure was reported to the exchange on Jan. 5, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AN2 Therapeutics Inc | Stephen David Prior | Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 1.00 per share. | 05 Jan 2026 | 3,604 | 61,944 | - | 1.0 | 3,615 | Common Stock |
| AN2 Therapeutics Inc | Stephen David Prior | Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 1.01 per share. | 05 Jan 2026 | 2,858 | 59,086 | - | 1.0 | 2,892 | Common Stock |
| AN2 Therapeutics Inc | Stephen David Prior | Chief Strategy Officer | 04 Nov 2025 | 765 | 65,548 | - | 1.1 | 872 | Common Stock | |
| AN2 Therapeutics Inc | Stephen David Prior | Chief Strategy Officer | 26 Feb 2025 | 56,000 | 56,000 | - | - | Stock Option (right to buy) | ||
| AN2 Therapeutics Inc | Stephen David Prior | Chief Strategy Officer | 26 Feb 2025 | 28,000 | 61,313 | - | 0 | Common Stock | ||
| AN2 Therapeutics Inc | Stephen David Prior | Chief Strategy Officer | 03 Jan 2025 | 2,029 | 33,313 | - | 1.3 | 2,721 | Common Stock | |
| AN2 Therapeutics Inc | Stephen David Prior | Chief Strategy Officer | 04 Nov 2024 | 20,250 | 20,250 | - | - | Stock Option (right to buy) | ||
| AN2 Therapeutics Inc | Stephen David Prior | Chief Strategy Officer | 04 Nov 2024 | 10,125 | 35,342 | - | 0 | Common Stock |